NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $57,442,000 | -13.9% | 3,766,666 | 0.0% | 39.74% | -8.2% |
| Q4 2021 | $66,708,000 | -15.7% | 3,766,666 | 0.0% | 43.30% | -1.9% |
| Q3 2021 | $79,175,000 | +6.6% | 3,766,666 | 0.0% | 44.14% | +549.2% |
| Q2 2021 | $74,279,000 | -32.2% | 3,766,666 | 0.0% | 6.80% | -35.4% |
| Q1 2021 | $109,497,000 | -4.0% | 3,766,666 | 0.0% | 10.53% | -82.5% |
| Q4 2020 | $114,111,000 | +90.4% | 3,766,666 | 0.0% | 60.06% | +20.4% |
| Q3 2020 | $59,928,000 | -19.4% | 3,766,666 | 0.0% | 49.90% | +3.6% |
| Q2 2020 | $74,354,000 | +60.1% | 3,766,666 | 0.0% | 48.16% | +2.9% |
| Q1 2020 | $46,443,000 | -33.3% | 3,766,666 | 0.0% | 46.79% | -11.6% |
| Q4 2019 | $69,646,000 | +33.5% | 3,766,666 | -0.0% | 52.94% | +21.2% |
| Q3 2019 | $52,168,000 | -5.4% | 3,766,667 | 0.0% | 43.68% | +14.2% |
| Q2 2019 | $55,144,000 | – | 3,766,667 | – | 38.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |